BG Growth Series – Physidia
Welcome to the “BG Growth Series”, where entrepreneurs tell us about their inspiring stories, share invaluable insights, and offer practical tips to navigate the growth journey.
Founded in 2010, Physidia is the leading French MedTech expert focused on developing, manufacturing, and marketing advanced home haemodialysis solutions. Physidia’s main mission is to enhance the comfort and freedom of dialysis patients, prioritising a higher quality of life by allowing patients to integrate dialysis seamlessly into their daily routines rather than structuring their lives around dialysis. Since receiving the CE mark approval in 2013, which means conformity with European health, safety, and environmental protection standards, close to 1 million dialysis cycles have been completed.
Their pioneering spirit is reflected in numerous patents and the development of the S3 monitor, the first 100% Made in France home haemodialysis system, which enables patients to maintain a high quality of life while managing their condition.
We sat down with the leaders and investors of Physidia to understand their commitment to improving patient outcomes, reflecting the company’s ethos. With an unwavering focus on innovation and patient-centric solutions, Physidia is reshaping the dialysis landscape with groundbreaking haemodialysis solutions for home use, challenging decades-old norms and revolutionising patient care.
Bryan Garnier played a crucial role in finding the right partner for Physidia’s growth, offering invaluable advisory services and growth strategy access. This major fundraising from Columna Capital, a prominent pan-European private equity investor, will accelerate the company’s development to become a global leader in the sector.
Join us on this captivating journey and learn how Bryan Garnier contributes to shaping a sustainable future, by partnering with innovative companies like Physidia. Bryan Garnier’s commitment to long-term success, deep industry knowledge, and global perspective enable companies to accelerate their growth and make a lasting impact.
Physidia’s journey showcases a fundamental shift in how we perceive and deliver healthcare. With visionary leadership and unwavering dedication, Physidia is poised to transform lives on a global scale.
Watch this episode of BG Growth Series to learn about Physidia at the forefront of dialysis treatment.
About Bryan, Garnier & Co
Bryan, Garnier & Co is a European growth investment bank that helps healthcare and technology companies become global champions. By combining extensive sector expertise with an entrepreneurial mindset, Bryan Garnier provides companies and their investors with independent growth strategic advice, and privileged access to buyers and capital in Europe, the US and Asia.
As a full-service investment bank, the firm offering includes private and public growth financing solutions, mergers and acquisitions (M&A) advisory, research insights, and institutional sales & execution. Founded in 1996, Bryan Garnier & Co is an independent partnership with around 200 employees located in major financial centres in Europe and the US.